# Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

> **NCT00724971** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 10 (actual)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** Inotuzumab Ozogamicin (CMC-544)
- **DRUG:** Rituximab (Rituxan)

## Key facts

- **NCT ID:** NCT00724971
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-04
- **Primary completion:** 2010-03-10
- **Final completion:** 2010-03-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00724971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00724971, "Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00724971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*